Alison Bateman-House, MPH, PhD, department of population health, NYU Langone Health, returns to discuss the ethics of “expanded access” and “Right To Try” when treating COVID-19, health care workers refusing to report to work if proper PPEs are not available, medical students graduating early to join the frontlines, practicing selective care due to scarce resources, and more.
Dr. Bateman-House was previously featured on a prior episode of the Outspoken Oncology discussing “right to try bill”
Dr Nabhan and Dr Bateman-House have no relevant financial disclosures. This podcast is produced by the Journal of Clinical Pathways.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
